In vitro and in vivo studies have shown that the introduction of an antisense oligonucleotide to human NOTCH 1 into the HPV16-positive cervical cancer cell line Ca Ski can inhibit tumour cell growth and reduce the tumourigenicity of the NOTCH 1 receptor. This evidence concerns the gene NOTCH1 and neoplasm.